• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novaccess Global Inc (OP:XSNX)

0.0001 UNCHANGED
Streaming Delayed Price Updated: 1:55 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Novaccess Global Inc

< Previous 1 2 Next >
News headline image
NovAccess Global Files Patent with Cedars-Sinai to Advance its Brain Cancer Fighting Vaccine Platform
May 21, 2024
Via ACCESSWIRE
News headline image
NovAccess Global Advisory on Annual Meeting of Shareholders
May 07, 2024
Via ACCESSWIRE
News headline image
NovAccess Global Announces New License to Advance its Immunotherapy Platform
April 30, 2024
Via ACCESSWIRE
News headline image
NovAccess Global Announces $10.7 Million Financing
January 02, 2024
Via ACCESSWIRE
News headline image
NovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory Board
November 10, 2023
Via ACCESSWIRE
News headline image
NovAccess Global Partners with BCN Biosciences to Expand Immunotherapy Platform
July 27, 2023
Via ACCESSWIRE
News headline image
NovAccess Global Lead Scientist Published in High-Profile Medical Journal for Cancer Vaccine Advancements
May 11, 2023
Via ACCESSWIRE
News headline image
Dr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon Award
March 15, 2023
Via ACCESSWIRE
News headline image
NovAccess Global to Participate in National Brain Tumor Society's Annual Glioblastoma Awareness Day
July 13, 2023
Via ACCESSWIRE
News headline image
NovAccess Global Partners with CKN Ventures to Expand its New AI-driven Precision Medicine Division
June 16, 2023
Via ACCESSWIRE
News headline image
NovAccess Global Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalized Healthcare Therapies
June 01, 2023
Via ACCESSWIRE
News headline image
NovAccess Global to Present at World Orphan Drug Congress
February 16, 2023
Via ACCESSWIRE
News headline image
NovAccess Global Leadership to Present at World Brain Mapping Foundation Annual Congress
February 03, 2023
Via ACCESSWIRE
News headline image
NovAccess Global Announces Fireside Chat with Dr. Christopher Wheeler, the Company’s Lead Scientist and President of its StemVax Therapeutics Division
January 05, 2023
Via ACCESSWIRE
News headline image
NovAccess Global Announces Initial Fireside Chat with Glioblastoma Patient Advocate
November 22, 2022
Via ACCESSWIRE
News headline image
NovAccess Global Announces Virtual Annual Shareholders' Meeting
November 08, 2022
Via ACCESSWIRE
News headline image
NovAccess Global Appoints Healthcare IP Consultant Dr. Peter Weinstein to Scientific Advisory Board
November 10, 2022
Via ACCESSWIRE
News headline image
NovAccess Global Receives FDA Approval of Orphan Drug Application for TLR-AD1
October 26, 2022
Via ACCESSWIRE
News headline image
NovAccess Global Announces Fireside Chat with Board Member Perspectives
October 20, 2022
Via ACCESSWIRE
News headline image
NovAccess Global Announces Fireside Chat Series for the Investment Community
September 29, 2022
Via ACCESSWIRE
News headline image
NovAccess Global Announces Effectiveness of Form S-1 Registration Statement
September 22, 2022
Via ACCESSWIRE
News headline image
NovAccess Global Announces Uplisting to OTCQB
August 10, 2022
Via ACCESSWIRE
News headline image
CORRECTION: NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1
July 19, 2022
Via ACCESSWIRE
News headline image
NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1
July 19, 2022
Via ACCESSWIRE
News headline image
CORRECTION: NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1
July 19, 2022
This corrects the release that ran earlier today, replacing the name of the executive quoted in the press release and other minor edits. 
From NovAccess Global Inc.
Via AccessWire
News headline image
NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1
July 19, 2022
Accelerating on the Path Toward Immunotherapy for Glioblastoma (Brain Cancer) 
From NovAccess Global Inc.
Via AccessWire
Topics Intellectual Property
News headline image
NovAccess Global CEO Dwain Irvin Featured on MoneyTV
June 14, 2022
CLEVELAND, OH / ACCESSWIRE / June 14, 2022 / NovAccess Global Inc. (OTC PINK:XSNX) announced that its Chief Executive Officer Dr. Dwain Irvin was a featured guest on MoneyTV, an... 
From NovAccess Global Inc.
Via AccessWire
News headline image
This Week on MoneyTV with Donald Baillargeon, 6/10
June 10, 2022
HOLLYWOOD, CA / ACCESSWIRE / June 10, 2022 / Cancer treatment, metaverse, coping; this week on MoneyTV with Donald Baillargeon 
From MoneyTV
Via AccessWire
News headline image
NovAccess Global to Participate in LD Micro Invitational XII Conference
May 19, 2022
CLEVELAND, OH / ACCESSWIRE / May 19, 2022 / NovAccess Global Inc. (OTC PINK:XSNX) announced that its Chief Executive Officer Dr. Dwain Irvin is scheduled to participate in the LD Micro Invitational XII... 
From NovAccess Global Inc.
Via AccessWire
Topics Intellectual Property
News headline image
NovAccess Global Stock Redemption and Expanded Board of Directors Reinforces Shareholder Value and Positions the Company to Accelerate Objectives
March 17, 2022
LOS ANGELES, CA / ACCESSWIRE / March 17, 2022 / NovAccess Global Inc. (OTC PINK:XSNX) announced today the closing of a series of transactions which results in the reduction of potential common stock... 
From NovAccess Global Inc.
Via AccessWire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap